Citation:Urba, Susan; Doroshow, James; Cripps, Christine; Robert, Francisco; Velez-Garcia, Enrique; Dallaire, Brian; Adams, David; Carlson, Randall; Grillo-Lopez, Antonio; Gyves, John; (1992). "Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck." Cancer Chemotherapy and Pharmacology 31 (2): 167-169. <http://hdl.handle.net/2027.42/46923>
Abstract: A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m 2 . The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.
